EGFR and lung carcinoma: Osimertinib and rociletinib, two anti-cancer drugs for lung cancer, work by shutting off mutant EGFR [49], which initially kills cancerous tumors, but the tumors rewire and activate Aurora kinase A, becoming cancerous growths again [50, 51].